Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure

Journal of Clinical Virology

Volumn 45, Issue 1, 2009, Pages 34-38

  Balduin, Melanie ^a   Oette, Mark ^b   Däumer, Martin P ^c   Hoffmann, Daniel ^d   Pfister, Herbert J ^a   Kaiser, Rolf ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Technische University   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Minority resistance; Non nucleoside reverse transcriptase inhibitors; Therapy na ve patients

Indexed keywords

ASPARAGINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LYSINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS STRAIN;

ADULT; AGED; ANTI-HIV AGENTS; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; GENES, POL; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE;

EID: 67349096369     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.03.002     Document Type: Article

References (28)

1. Hecht F.M., Grant R.M., Petropoulos C.J., Dillon B., Chesney M.A., Tian H., et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 339 5 (1998) 307-311
2. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347 6 (2002) 385-394
3. Oette M., Kaiser R., Daumer M., Petch R., Fatkenheuer G., Carls H., et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41 5 (2006) 573-581
4. Sagir A., Oette M., Kaiser R., Daumer M., Fatkenheuer G., Rockstroh J.K., et al. Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 60 4 (2007) 843-848
5. Wensing A.M., and Boucher C.A. Worldwide transmission of drug-resistant HIV. AIDS Rev 5 3 (2003) 140-155
6. Wensing A.M., van de Vijver D.A., Angarano G., Asjo B., Balotta C., Boeri E., et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192 6 (2005) 958-966
7. Violin M., Cozzi-Lepri A., Velleca R., Vincenti A., D'Elia S., Chiodo F., et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 18 2 (2004) 227-235
8. Grant R.M., Hecht F.M., Warmerdam M., Liu L., Liegler T., Petropoulos C.J., et al. Time trends in primary HIV-1 drug resistance among recently infected persons. Jama 288 2 (2002) 181-188
9. Domingo E.B.C., Holland J.J., and Eigen M. Quasispecies and RNA virus evolution: principles and consequences (2001), Editor Landes Bioscience, Austin, Texas
10. Clavel F., and Hance A.J. HIV drug resistance. N Engl J Med 350 10 (2004) 1023-1035
11. Deeks S.G., Grant R.M., Wrin T., Paxinos E.E., Liegler T., Hoh R., et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 17 3 (2003) 361-370
12. Hance A.J., Lemiale V., Izopet J., Lecossier D., Joly V., Massip P., et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 75 14 (2001) 6410-6417
13. Charpentier C., Dwyer D.E., Mammano F., Lecossier D., Clavel F., and Hance A.J. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol 78 8 (2004) 4234-4247
14. Metzner K.J., Bonhoeffer S., Fischer M., Karanicolas R., Allers K., Joos B., et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 188 November 3(10) (2003) 1433-1443 [Epub 2003]
15. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267 5197 (1995) 483-489
16. Briones C., de Vicente A., Molina-Paris C., and Domingo E. Minority memory genomes can influence the evolution of HIV-1 quasispecies in vivo. Gene 384 (2006) 129-138
17. Schuurman R., Brambilla D., de Groot T., Huang D., Land S., Bremer J., et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 18 4 (2002) 243-248
18. Schuurman R., Demeter L., Reichelderfer P., Tijnagel J., de Groot T., and Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 37 7 (1999) 2291-2296
19. Lecossier D., Shulman N.S., Morand-Joubert L., Shafer R.W., Joly V., Zolopa A.R., et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 38 1 (2005) 37-42
20. Metzner K.J., Rauch P., Walter H., Boesecke C., Zollner B., Jessen H., et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 19 16 (2005) 1819-1825
21. Bergroth T., Sonnerborg A., and Yun Z. Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. J Virol Methods 127 1 (2005) 100-107
22. Dykes C., Najjar J., Bosch R.J., Wantman M., Furtado M., Hart S., et al. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J Infect Dis 189 6 (2004) 1091-1096
23. Oette M., Kaiser R., and Häussinger D. Resistenz in der HIV-Therapie: Diagnostik und Management (2003), Editor UNI-MED, Bremen
24. Balduin M., Sierra S., Daumer M.P., Rockstroh J.K., Oette M., Fatkenheuer G., et al. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy. J Clin Virol 34 (2005) 277-287
25. Aleman S., Soderbarg K., Visco-Comandini U., Sitbon G., and Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 16 7 (2002) 1039-1044
26. Balotta C., Berlusconi A., Pan A., Violin M., Riva C., Colombo M.C., et al. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther 5 1 (2000) 7-14
27. Erice A., Mayers D.L., Strike D.G., Sannerud K.J., McCutchan F.E., Henry K., et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 328 16 (1993) 1163-1165
28. Nicastri E., Sarmati L., d'Ettorre G., Palmisano L., Parisi S.G., Uccella I., et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 69 1 (2003) 1-6